{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-041275","form_type":"8-K","ticker":"OKUR","cik":"0001637715","company_name":"OnKure Therapeutics, Inc.","filed_at":"2023-08-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.643444+00:00","generated_at":"2026-06-11T17:48:49.448568+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Reneo Q2 net loss $19.5M; STRIDE topline results expected Q4 2023","bullets":["Net loss $19.5M ($0.65/share) vs $12.3M ($0.50) in Q2 2022.","Cash and investments $142.7M as of June 30; raised $68.3M gross in May offering.","Topline data from pivotal mavodelpar STRIDE study in PMM due in Q4 2023.","Over 130 patients enrolled in STRIDE AHEAD OLE study; criteria expanded to nDNA defects.","R&D expenses $14.4M (up from $8.1M) driven by clinical and manufacturing costs for mavodelpar."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-041275","json":"https://secwatch.observer/filing/0000950170-23-041275.json","markdown":"https://secwatch.observer/filing/0000950170-23-041275.md","text":"https://secwatch.observer/filing/0000950170-23-041275.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1637715/000095017023041275/0000950170-23-041275-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1637715/000095017023041275/rphm-20230810.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T17:48:49.448568+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"141be55e4938e3d4824ae7fbb7367f0881b64fe0","claim":"OnKure Therapeutics, Inc. reported the second quarter ended June 30, 2023 results: net income net loss of $19.5 million, or $0.65 per share, EPS $0.65 per share.","evidence_excerpt":"On August 10, 2023, Reneo Pharmaceuticals, Inc. (the “Company”) issued a press release reporting the Company’s financial results for the second quarter ended June 30, 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1637715/000095017023041275/0000950170-23-041275-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the second quarter ended June 30, 2023"},{"label":"Net income","value":"net loss of $19.5 million, or $0.65 per share"},{"label":"EPS","value":"$0.65 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}